Depth of Response Correlates with Improved Outcomes for Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Demographics (3)
- AGE - Age (phv00555631.v1.p1)
- COLLECTION_AGE - Subject's age at time of sample collection (phv00555638.v1.p1)
- SEX - Sex (phv00555624.v1.p1)
Disease Events (1)
- AFFECTION_STATUS - Affection status for smoldering multiple myeloma (phv00555628.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00555632.v1.p1)
Other (16)
- ANALYTE_TYPE - Analyte type (phv00555635.v1.p1)
- BIOCHEMICAL_PROGRESSION - Index of biochemical progression events (phv00555629.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00555634.v1.p1)
- COMMENT1 - Library Type (phv00555641.v1.p1)
- COMMENT2 - 10x Kit version (phv00555642.v1.p1)
- CONSENT - Type of consent (phv00555623.v1.p1)
- HISTOLOGICAL_TYPE - Histological type (phv00555637.v1.p1)
- IS_TUMOR - Tumor status (phv00555636.v1.p1)
- SAMPLE_ID - Sample ID (phv00555633.v1.p1)
- SAMPLE_ID - Sample ID (phv00555626.v1.p1)
- SLIM_CRAB_PROGRESSION - Index of overt myeloma progression events (phv00555630.v1.p1)
- SUBJECT_ID - Subject ID (phv00555627.v1.p1)
- SUBJECT_ID - Subject ID (phv00555622.v1.p1)
- SUBJECT_ID - Subject ID (phv00555625.v1.p1)
- TIMEPOINT - Timepoint at time of collection (phv00555639.v1.p1)
- TUMOR_STAGE - Stage of disease (phv00555640.v1.p1)